

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Nexavar (sorafenib)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Nexavar (sorafenib)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Nexavar (sorafenib) may be approved if the following criteria are met:

- I. Individual has a diagnosis of one of the following:
 - A. Acute Myeloid Leukemia (AML) - relapsed/refractory disease with FMS-like tyrosine kinase-3/internal tandem duplication (FLT3/ITD) mutation and results are confirmed (NCCN 2A); **OR**
 - B. Bone Cancer – relapsed/refractory or metastatic Osteosarcoma (NCCN 2A); **OR**
 - C. Bone Cancer – recurrent Chordoma; **OR**
 - D. Advanced Renal Cell Carcinoma (RCC); **OR**
 - E. Advanced or unresectable hepatocellular carcinoma (HCC); **OR**
 - F. Thyroid Carcinoma, with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) disease that is refractory to radioactive iodine treatments; **OR**
 - G. Soft Tissue Sarcoma (NCCN 2A).

Note: Nexavar in combination with carboplatin and paclitaxel is contraindicated in patients with squamous cell lung cancer.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2016.
URL: <http://www.clinicalpharmacology.com>. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: 4/2018

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2018 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.